Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma

Summary

The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and the maximal tolerated dose (MTD) of VAL-083 in patients with recurrent malignant glioma. Pharmacokinetic (PK) properties will be explored and tumor responses to treatment will be evaluated.

Timeline

Start

2011-10

Primary completion

2015-12

Completion

2016-10

Drugs

Indications